The Latest Developments in Migraine Research

You are currently watching a preview of this interview. Unlock the full version by upgrading to an Access Pass bundle! Get FREE access to 8 expert interviews from Day 1 and Day 2 when you register today!

Key Questions
  • What entities are behind the majority of research funding for migraine?
  • What is behind the explosion of targeted migraine medications and devices in recent years?
  • Why is it important for more research to be done on combining migraine medications?
  • What research is being conducted on the combination of Botox with the new gepants, or the combination of gepants with CGRP monoclonal antibodies?
  • What is the latest research on medications like rimegepant (Nurtec), the first of the modern medications to be approved for both acute and preventive use?
  • What is the advantage of Nurtec used preventively over some of the older preventives, like beta blockers or topiramate?
  • What are some older medications that have come out in new formulations or delivery systems?
  • Why is the upper nasal cavity of such interest recently in new migraine medication-delivery systems?
  • What does new research tell us about omega-3 and omega-6 fatty acids and migraine?
  • Has there been enough evidence to support a ketogenic diet for migraine?
  • What does the research say about behavioral therapies for migraine management?
  • What are some of the gaps in migraine research?
  • How will these gaps be addressed in future migraine research?
  • What are some of the newer targets in the migraine research pipeline?
Interview Notes

Find more about Richard Lipton, MD and his work here:

Treatments Mentioned
  • Atogepant
  • Beta blockers (propranolol)
  • Botox
  • Celecoxib
  • CBT
  • CGRP monoclonal antibodies
  • Combination therapies
  • DHE
  • Ditans
  • Divalproex sodium
  • Eptinezumab (Vyepti)
  • Gepants
  • Neuromodulation devices
  • NSAIDs
  • Onzetra-Xsail
  • Rimegepant (Nurtec)
  • SPG blocks
  • Sumatriptan (subcutaneous and nasal)
  • Trudhesa
  • Zavegepant
  • Zolmitriptan

Please note: The Migraine World Summit’s aim is to bring you a variety of perspectives and expertise, independent of bias or judgment. Alternative theories presented in this video have not been medically reviewed. Views expressed in this interview do not necessarily represent the views of the Migraine World Summit. Please always consult your health care professional and do your own research before making changes to your treatment plan.


Richard B. Lipton, MD

Professor of Neurology & Director of the Montefiore Headache Center, and Director of the Division of Cognitive Aging and Dementia
Albert Einstein College of Medicine

Dr. Richard B. Lipton is an expert in headache and migraine management, as well as cognitive aging and dementia. He serves as the director of the Montefiore Headache Center and holds the prestigious Edwin S. Lowe chair in neurology at Albert Einstein University in New York. Internationally acclaimed for his contributions to headache diagnosis, classification, epidemiology, and treatment, Dr. Lipton has an impressive bibliography with 11 books and over 1,000 articles in indexed journals. His textbook, Headache in Clinical Practice, earned him the Medical Book Award from the British Medical Association.

He is past president of the American Headache Society (AHS), and is an associate editor for Cephalalgia: An International Journal of Headache. Additionally, he contributes to several other editorial boards, including for Neurology. His outstanding research has been recognized six times with the Harold G. Wolff Lecture Award from the AHS. Beyond neurology, Dr. Lipton is also a professor in psychiatry, behavioral sciences, epidemiology, and population health at the Albert Einstein College of Medicine.

Purchase full access to the entire 2024 Summit to unlock:

  • All expert interviews with separate audio (MP3) files & transcripts
  • 30 extended, uncut interview editions with hours more expert footage
  • Lifetime on-demand access with no annual fee to 2024 Summit
  • Interview Summaries
  • Treatment Directory & Guidelines
  • And much more!
Order your 2024 Access Pass

Related Talks for: Day 8 (2022)

Staying Hopeful: Treatment Burnout in Chronic Disease

Dawn C. Buse, PhD

How Women’s Hormones Affect Migraine

Jelena Pavlović, MD, PhD

The Latest Cannabis Research for Migraine

Nathaniel M. Schuster, MD

We support research for better treatments and a cure while advocating to improve the lives of those struggling with cluster headaches.

Learn more

View more/less

The VIP Treatment Directory lists over 300 options including treatments, therapies, devices, procedures, strategies and approaches to treat or prevent migraine. Only available with the VIP Access Pass. Learn more at the order page.

View more/less

Leave a comment

Back to top